With the multi N/C 2100S pharma and 3100 pharma, two new device models are being introduced

The appeal of developing improved drugs to promote helpful reactions or prevent harmful ones has driven organic chemists to better understand how to synthetically create these molecules and reactions in the laboratory

Sygnature’s Computational Chemistry department have spent the past year looking at how augmented reality can be applied to drug discovery

The biomanufacturing platform uses bursting bacteria and a shrinking capsule to produce targeted proteins

Novel nano-tool provides a new approach to use cell-based nanomedicines for effcient cancer chemotherapy

Researchers set out to better develop building blocks called polyene substructures

CORNERSTONE program integrates process development expertise and novel technology to remove development bottlenecks in the manufacture of Gene Therapy Medicinal Products (GTMPs) 

Single crystal X-ray diffraction analysis of low-molecular-weight active pharmaceutical ingredient crystal structures requires a single crystal of 10 μm or more, making microcrystal analysis challenging

Gold-based molecules that target cancer cells and leave healthy cells unharmed—a step towards precision cancer drugs with fewer toxic side effects

Flexible, modular system, designed for 21CFR Part 11 compliance